{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-064509","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.243515+00:00","generated_at":"2026-06-01T09:07:45.410973+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Sagimet Biosciences updates investor presentation; no new material data disclosed","bullets":["Filed an updated slide presentation as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.","Presentation titled 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne and Cancer' dated May 2024.","No specific financial or clinical data from the presentation were provided in the filing text."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-064509","json":"https://secwatch.observer/filing/0001104659-24-064509.json","markdown":"https://secwatch.observer/filing/0001104659-24-064509.md","text":"https://secwatch.observer/filing/0001104659-24-064509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924064509/0001104659-24-064509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924064509/tm2415356d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:07:45.410973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}